AndroGel in Men 65 and Older: What the Evidence Actually Shows

What Happens to Testosterone Levels as Men Age?

Serum total testosterone declines at roughly 1% to 2% per year after age 40, so a man of 70 may carry 30% to 40% less circulating testosterone than he did at 40. The European Male Aging Study (N=3,369) found that 2.1% of men aged 40 to 79 met biochemical and symptomatic criteria for late-onset hypogonadism, with prevalence rising steeply after age 70 (Wu et al., NEJM 2010).[1]

Sex hormone-binding globulin (SHBG) rises with age, which suppresses free testosterone even when total testosterone remains borderline. Free testosterone measurements therefore carry more diagnostic weight in men over 65 than in younger patients (Bhasin et al., JCEM 2018 Endocrine Society Guidelines).[2]

The Diagnostic Threshold Question

The Endocrine Society defines biochemical hypogonadism as a morning total testosterone below 300 ng/dL on two separate measurements, confirmed before 10 a.m. A man of 72 with total testosterone of 280 ng/dL and symptoms including low libido, fatigue, and reduced bone mineral density meets criteria for a therapeutic trial, but age-related decline alone is not a stand-alone indication for AndroGel.[2]

Symptom Overlap in Older Men

Fatigue, low mood, and reduced libido are common in older men for reasons that have nothing to do with testosterone: sleep apnea, hypothyroidism, depression, and metabolic syndrome all produce the same symptom cluster. Ruling these out before prescribing AndroGel is not optional; it is the standard of care articulated in the 2018 Endocrine Society Clinical Practice Guideline.[2]

How AndroGel Works in the Aging Male Body

AndroGel delivers testosterone transdermally through a hydroalcoholic gel applied once daily to the shoulders, upper arms, or abdomen. The 1.62% formulation (AndroGel 1.62%) achieves mean steady-state serum testosterone of approximately 500 to 700 ng/dL in clinical trials when dosed at 40.5 mg to 81 mg daily (FDA label, AndroGel 1.62%, NDA 202763).[3]

Pharmacokinetic Changes After 65

Older skin has reduced hydration, thinner dermis, and lower subcutaneous blood flow. These changes may reduce transdermal absorption by 10% to 20% compared with men in their 40s, though published pharmacokinetic data specific to men over 65 remain sparse. The FDA label for AndroGel 1.62% states no formal geriatric pharmacokinetic studies were conducted and recommends conservative dose titration in older adults.[3]

Serum Level Targets

The TTrials protocol targeted testosterone levels of 500 to 800 ng/dL in men aged 65 and older. Keeping levels within the mid-normal range rather than pushing toward the high-normal ceiling reduces polycythemia risk, which escalates sharply when hematocrit climbs above 50% (Snyder et al., NEJM 2016).[4]

Application Site Precautions in Older Households

Transfer to female partners or grandchildren through skin-to-skin contact is a documented concern. The FDA issued a Black Box Warning update requiring patients to wash application sites before contact and to cover them with clothing (FDA Drug Safety Communication, 2009).[5] This warning carries particular weight in multigenerational households where older men may have frequent contact with young grandchildren.

The Testosterone Trials: The Core Evidence Base for Older Men

The TTrials (Testosterone Trials) represent the most rigorous evidence set for AndroGel use in men aged 65 and older. Seven coordinated, placebo-controlled trials enrolled 790 men with average age 72 and confirmed low testosterone (<275 ng/dL) plus at least one of three age-related impairments: reduced sexual function, low vitality, or impaired physical function (Snyder et al., NEJM 2016).[4]

Sexual Function Trial Results

The Sexual Function Trial (N=470) showed that testosterone-treated men scored significantly higher on the Psychosexual Daily Questionnaire for sexual desire and activity at 12 months compared with placebo (P<0.001 for sexual desire). The effect size was modest: roughly 1.4 additional sexual activities per month in the treated group. Men whose baseline testosterone was lowest showed the greatest gains.[4]

Physical Function Trial Results

The Physical Function Trial found no statistically significant difference between testosterone and placebo on the primary outcome (6-minute walk distance) at 12 months, though a prespecified secondary measure of stair-climbing power did improve. The NEJM editorial accompanying this publication noted that "the trial was not powered for clinical events and should not be used to draw conclusions about safety."[4]

Vitality Trial Results

The Vitality Trial (N=474) used the FACIT-Fatigue scale as its primary endpoint. Testosterone produced no significant improvement over placebo at 12 months. This negative result is clinically meaningful: older men who initiate AndroGel primarily to address fatigue or low energy are unlikely to benefit based on trial data.[4]

Cardiovascular Considerations in Men Over 65

Cardiovascular risk is the central safety concern for AndroGel in older men. The FDA added a label warning in 2015 after a meta-analysis and post-marketing reports linked testosterone therapy to increased rates of non-fatal myocardial infarction, stroke, and death in older men (FDA Drug Safety Communication 2015).[6]

Coronary Artery Plaque: TTrials Cardiovascular Sub-Study

The TTrials Cardiovascular Sub-Study (N=170) used coronary CT angiography at baseline and 12 months. Noncalcified plaque volume increased by a mean of 41% in the testosterone arm versus 13% in the placebo arm (P=0.002) (Budoff et al., JAMA 2017).[7] The clinical significance of this change remains debated, but it raises a meaningful flag for men over 65 who already carry subclinical atherosclerosis.

The TRAVERSE Trial

Published in 2023, the TRAVERSE trial (N=5,198, mean age 63.7, all with pre-existing or high risk of cardiovascular disease) found that testosterone replacement therapy did not increase rates of major adverse cardiovascular events (MACE) compared with placebo over a mean follow-up of 33 months (Lincoff et al., NEJM 2023).[8] TRAVERSE also detected higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm. For men over 65, those specific signals deserve weight even if aggregate MACE was non-inferior.

Polycythemia and Thrombosis Risk

Testosterone stimulates erythropoiesis. In older men, who often have borderline renal function and reduced plasma volume, hematocrit can rise to thrombotic levels faster than in younger patients. The Endocrine Society recommends withholding AndroGel and reducing the dose when hematocrit exceeds 54%.[2] Baseline hematocrit should be measured before prescribing, and rechecked at three months.

Bone Density: A Clearer Benefit Signal

Among all the TTrials outcomes, bone mineral density showed the most consistent improvement. The TTrials Bone Trial (N=211) found that lumbar spine BMD increased 7.5% in the testosterone group versus 1.0% in the placebo group at 12 months (P<0.001). Femoral neck BMD increased 4.1% versus 0.6% (P<0.001) (Snyder et al., JCEM 2017).[9]

Clinical Relevance for Fracture Prevention

Whether these BMD gains translate to fewer fractures in older men has not been established in a prospective trial. The TTrials were 12 months long, and fracture trials typically require three or more years. The 2020 American College of Physicians guideline on osteoporosis screening does not recommend testosterone as a primary pharmacological agent for fracture prevention in older men (Qaseem et al., Annals of Internal Medicine 2017).[10]

Co-prescribing Considerations

Men over 65 with confirmed hypogonadism and osteopenia or osteoporosis may be candidates for both AndroGel and a bisphosphonate. The decision should account for baseline DXA results, fall risk, and renal function. A FRAX score above 20% for major osteoporotic fracture is the Endocrine Society threshold triggering pharmacological bone protection consideration.[2]

Cognitive Function and Mood: Limited Evidence

The TTrials Cognitive Function Trial (N=493) tested whether testosterone improved verbal memory, visual memory, and spatial ability in men 65 and older over 12 months. Testosterone did not significantly improve any cognitive domain compared with placebo (Resnick et al., NEJM 2017).[11] This finding challenges the idea, prevalent in direct-to-consumer marketing, that testosterone gel restores mental sharpness in older men.

Depression and Mood

A sub-analysis of TTrials data found modest improvement in depressive symptoms in men whose PHQ-9 scores were elevated at baseline. The effect was small and not found in men with normal baseline mood. The Endocrine Society does not list mood improvement as a primary indication for testosterone in older men.[2]

A Decision Framework for Geriatric Candidates

Prescribers evaluating AndroGel for a man over 65 can use the following four-domain screen before initiating therapy:

1. Biochemical confirmation. Two morning total testosterone values below 300 ng/dL, with free testosterone measured if SHBG is elevated.
2. Symptom specificity. Symptoms attributable to hypogonadism rather than comorbidities (screen for sleep apnea, hypothyroidism, depression, metabolic syndrome first).
3. Cardiovascular risk stratification. Coronary calcium score or ASCVD 10-year risk; consider deferring in men with recent ACS or uncontrolled heart failure.
4. Baseline labs. Hematocrit, PSA, lipid panel, LH, FSH, and prolactin before the first prescription.

Prostate Safety in Older Men

Testosterone does not cause prostate cancer, but it can accelerate growth of pre-existing androgen-sensitive tumors. Men over 65 carry a higher background prevalence of subclinical prostate cancer than younger men. The FDA label for AndroGel contraindicates use in men with known or suspected prostate cancer (FDA label, NDA 202763).[3]

PSA Monitoring

PSA should be measured at baseline, at three months, and then annually. A PSA rise of more than 1.4 ng/mL in any 12-month period, or a PSA above 4.0 ng/mL at any point, warrants urology referral and possible discontinuation. The Endocrine Society specifically calls out men over 65 as requiring tighter PSA surveillance given higher prostate cancer prevalence.[2]

Benign Prostatic Hyperplasia

Testosterone may worsen lower urinary tract symptoms in men with BPH. Men with moderate to severe LUTS (International Prostate Symptom Score above 19) are generally not candidates for AndroGel until LUTS is controlled.[2]

Dosing and Titration in Men Over 65

The starting dose of AndroGel 1.62% in older men is typically 40.5 mg (two pump actuations) applied once daily. Serum testosterone is checked two weeks after initiation, targeting 400 to 700 ng/dL. If levels remain below 400 ng/dL and no safety flags have appeared, the dose may be increased to 60.75 mg (three actuations) (FDA label, NDA 202763).[3]

Older men should have hematocrit checked at three months. If hematocrit exceeds 54%, the dose should be reduced by one actuation and rechecked in six weeks. Dose escalation above 81 mg daily in men over 65 requires explicit clinical justification given the plaque and polycythemia data above.[4]

The Endocrine Society 2018 guideline states: "We recommend against starting testosterone therapy in patients with hematocrit greater than 48%", a threshold that many older men may approach at baseline, particularly those with chronic obstructive pulmonary disease or sleep apnea.[2]

Monitoring Schedule for Geriatric Patients on AndroGel

| Timepoint | Tests Required | |---|---| | Baseline | Total T, free T, LH, FSH, prolactin, hematocrit, PSA, lipids, BMI | | 3 months | Total T (mid-cycle), hematocrit, PSA | | 6 months | Total T, hematocrit, PSA, blood pressure | | 12 months and annually | Full panel including lipids, DXA if indicated, reassess indication |

Source: Endocrine Society Clinical Practice Guideline 2018 and AndroGel 1.62% FDA prescribing information.[2][3]

When to Stop AndroGel in an Older Man

Discontinuation is appropriate when any of the following occur: hematocrit exceeds 54% on dose reduction, PSA rises more than 1.4 ng/mL over 12 months, confirmed prostate or breast cancer diagnosis, untreated severe sleep apnea, uncontrolled heart failure, or new diagnosis of polycythemia vera. The Endocrine Society also recommends stopping if no symptomatic improvement is seen after three to six months of treatment at adequate serum levels.[2]

Rebound effects after stopping are usually mild in older men given the attenuated hypothalamic-pituitary-gonadal axis response at this age. Still, abrupt discontinuation after more than 12 months of therapy may worsen fatigue and mood for four to eight weeks.